What is the official website of Novartis Medical ?

The official website of Novartis Medical is https://www.novartis.com/.

What is Novartis Medical's cybersecurity risk score?

Novartis Medical has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Medical experienced?

According to Rankiteo, Novartis Medical currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Medical been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Medical has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Medical have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Medical is not certified under SOC 2 Type 1.

Does Novartis Medical have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Medical does not hold a SOC 2 Type 2 certification.

Does Novartis Medical comply with GDPR ?

According to Rankiteo, Novartis Medical is not listed as GDPR compliant.

Does Novartis Medical have PCI DSS certification ?

According to Rankiteo, Novartis Medical does not currently maintain PCI DSS compliance.

Does Novartis Medical comply with HIPAA ?

According to Rankiteo, Novartis Medical is not compliant with HIPAA regulations.

Does Novartis Medical have ISO 27001 certification ?

According to Rankiteo,Novartis Medical is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Medical operate in ?

Novartis Medical operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Medical have ?

Novartis Medical employs approximately None employees people worldwide.

Does Novartis Medical own any subsidiaries ?

Novartis Medical presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Medical have ?

Novartis Medical's official LinkedIn profile has approximately 4,621 followers.

What is the NAICS classification code for Novartis Medical ?

Novartis Medical is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Medical have a Crunchbase profile ?

No, Novartis Medical does not have a profile on Crunchbase.

Does Novartis Medical have a LinkedIn profile ?

Yes, Novartis Medical maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-medical.

How many cybersecurity incidents has Novartis Medical experienced ?

As of July 10, 2026, Rankiteo reports that Novartis Medical has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Medical have ?

Novartis Medical has an estimated 5,706 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Medical faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Medical

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Novartis Medical Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Committed to providing medical & scientific disease education to healthcare professionals globally. See our community guidelines: https://bit.ly/3PAq2J7 If you have a medical inquiry, please contact your local Novartis Medical contact via https://www.novartis.com/healthcare-professionals/novartis-medical-information. Our posts are for healthcare professionals only. • Please be patient; sometimes responses take time. • Please do not include your personal information in your posts. • We will respond to your questions/comments M-F, 9a-5p CET (no holidays). • The purpose of our posts is to share disease state education, medical information and scientific data, and congress updates. We reserve the right to hide or remove any post that

Novartis Medical A.I CyberSecurity Scoring

Scoring History

Novartis Medical

Novartis Medical CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Medical

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Medical

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Medical in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Medical in 2026.

Incident Types Novartis Medical vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Medical in 2026.

Incident History - Novartis Medical (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Medical Subsidiaries

Novartis Medical

Pharmaceutical Manufacturing

Website: https://www.novartis.com/

Company Size: 10,001+ employees

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Loading…

Novartis Medical Similar Companies

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Loading…

NEWS

Novartis Medical CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 02, 2026 08:00 AM

Novartis Defends Hypertension Patent Against Teva Claims

Novartis has pushed back against Teva's invalidity claims over a supplementary protection certificate that extends protection for a...

Read Article

August 13, 2025 07:00 AM

Dräger’s Atlan A350 Series Gains US DoD Security Certification

Dräger's Atlan A350 anesthesia workstation series earns US DoD cybersecurity certification, securing patient data in operating rooms.

Read Article

August 11, 2025 07:00 AM

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Cencora, The Lash Group, and their affiliates have agreed to pay $40 million to settle class action data breach litigation over a February...

Read Article

February 18, 2025 08:00 AM

HMRI and Novartis Australia sign MoU to expedite medical research

The Hunter Medical Research Institute (HMRI) has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research to drive...

Read Article

December 10, 2024 08:00 AM

Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging

Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and...

Read Article

October 17, 2024 07:00 AM

Brave new world: Building Europe’s capacities for defence and security R&D

For the first time since the end of the Cold War, the next period of EU politics and policy-making will be dominated by security issues.

Read Article

September 04, 2024 07:00 AM

M&A roundup: Siemens to buy Novartis imaging for $223M, and more

Siemens Healthineers agreed to buy drug giant Novartis's nuclear diagnostics imaging business. Meanwhile, Enlitic announced it plans to acquire a radiology...

Read Article

July 19, 2024 07:00 AM

Pharma companies report various levels of exposure to IT outage caused by CrowdStrike, Microsoft

While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced...

Read Article

May 28, 2024 07:00 AM

Data breach at pharma partner Cencora puts sensitive patient information at risk

A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-59858

SUMMARY

Vim is an open source, command line text editor. Prior to 9.2.0735, the C omni-completion script in runtime/autoload/ccomplete.vim interpolates the typeref: or typename: extension field of a tags entry, without escaping, into a :vimgrep pattern that is run through :execute. Because :vimgrep honors the bar as a command separator, a crafted tag field can close the search pattern and append an arbitrary Ex command; opening a hostile .c file whose project tags file contains such an entry and invoking C omni-completion runs that command as the editing user. This issue is fixed in version 9.2.0735.

Published

Date2026-07-09

Updated

Date2026-07-09

RISK INFORMATION (Score: )

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-59857

SUMMARY

Vim is an open source, command line text editor. Prior to 9.2.0725, the single-byte branch of spell_soundfold_sal() in src/spell.c translates a word through a spell file's SAL sound-folding rules into a caller-owned result buffer, but its result writes are guarded with reslen < MAXWLEN, allowing reslen to reach MAXWLEN before res[reslen] = NUL writes one byte past the end of the MAXWLEN-element stack buffer. A boundary-length word passed to soundfold(), or reached via sound-based spell suggestion while a SAL-based spell language is active under a non-multibyte 8-bit encoding, can corrupt the eval_soundfold() stack frame and crash the editor. This issue is fixed in version 9.2.0725.

Published

Date2026-07-09

Updated

Date2026-07-09

RISK INFORMATION (Score: )

cvss4

Base Score: 5.6

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:A/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-59856

SUMMARY

Vim is an open source, command line text editor. Prior to 9.2.0736, the PHP omni-completion script in runtime/autoload/phpcomplete.vim interpolates a class or trait name, taken from the contents of the edited buffer, into a search() pattern that is run via win_execute() without escaping. A name containing a single quote can terminate the search() string argument early, and because the bar is honored as an Ex command separator, the remainder of the name is run as Ex commands; via the :! command this allows arbitrary operating-system command execution when a victim opens a crafted PHP file and invokes omni-completion. This issue is fixed in version 9.2.0736.

Published

Date2026-07-09

Updated

Date2026-07-09

RISK INFORMATION (Score: )

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-59855

SUMMARY

SiYuan is an open-source personal knowledge management system. Prior to 3.7.1, Asset.render in app/src/asset/index.ts interpolates the unsanitized this.path value into HTML assigned to innerHTML, allowing a crafted asset link containing a double quote to break out of the src attribute, inject an event handler, and execute JavaScript that can run OS commands in the Electron renderer. This issue is fixed in versions 3.7.1-alpha.2 and 3.7.1.

Published

Date2026-07-09

Updated

Date2026-07-09

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-59854

SUMMARY

SiYuan is an open-source personal knowledge management system. Prior to 3.7.1, POST /api/file/globalCopyFiles accepts attacker-supplied absolute source paths and relies on util.IsSensitivePath in kernel/util/path.go, whose denylist misses common home-directory credential files such as .git-credentials, .netrc, .pgpass, .kube/config, .docker/config.json, and .gnupg, allowing an authenticated administrator or API-token user to copy those files into the workspace and exfiltrate them through the file API. This issue is fixed in versions 3.7.1-alpha.2 and 3.7.1.

Published

Date2026-07-09

Updated

Date2026-07-09

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…